Multidrug-resistant organisms: MRSA, VRE, ESBL and CPE
The four MROs Australian hospitals track, the mechanism behind each, how mechanism drives treatment choice (vancomycin AUC, MERINO, carbapenemase-specific agents), and how they rank for isolation.
Tier 1Medical sciences concept
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
Loading the rest of the note…
Finished reading?
Sources
- Therapeutic Guidelines: Antibiotic (2025 update)AU/NZTherapeutic Guidelines Limited, 2025
- Recommendations for the control of carbapenemase-producing Enterobacterales (CPE): a guide for acute care health service organisationsAU/NZAustralian Commission on Safety and Quality in Health Care, 2021
- Australian Guidelines for the Prevention and Control of Infection in HealthcareAU/NZNHMRC and Australian Commission on Safety and Quality in Health Care, 2019, updated 2021
- CARAlert annual report 2025AU/NZAustralian Commission on Safety and Quality in Health Care, 2026
- IDSA 2026 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative InfectionsInfectious Diseases Society of America, 2026
- Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance (MERINO)JAMA (Harris et al., 2018;320:984-94), 2018
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guidelineAmerican Journal of Health-System Pharmacy (Rybak et al., 2020;77:835-64), 2020
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback